SERZONE Drug Patent Profile
✉ Email this page to a colleague
When do Serzone patents expire, and what generic alternatives are available?
Serzone is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in SERZONE is nefazodone hydrochloride. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nefazodone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Serzone
A generic version of SERZONE was approved as nefazodone hydrochloride by TEVA on September 16th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SERZONE?
- What are the global sales for SERZONE?
- What is Average Wholesale Price for SERZONE?
Summary for SERZONE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Clinical Trials: | 1 |
Patent Applications: | 1,195 |
DailyMed Link: | SERZONE at DailyMed |
Recent Clinical Trials for SERZONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Boston University | Phase 2 |
Boston Medical Center | Phase 2 |
US Patents and Regulatory Information for SERZONE
Expired US Patents for SERZONE
International Patents for SERZONE
See the table below for patents covering SERZONE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Belgium | 900038 | ⤷ Sign Up | |
Netherlands | 970014 | ⤷ Sign Up | |
United Kingdom | 2184447 | A SUBSTITUTED TRIAZOLONE | ⤷ Sign Up |
Ireland | 820589 | ⤷ Sign Up | |
Belgium | 892503 | ⤷ Sign Up | |
United Kingdom | 8703633 | ⤷ Sign Up | |
South Korea | 880001374 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |